(redirected from Cyclin-dependent kinase)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to kinase

an enzyme that catalyzes the conversion of a proenzyme to an active enzyme

Related Words

References in periodicals archive ?
Arif, "Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5," Biochemical Pharmacology, vol.
Sheldrake et al., "The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl1 to override pro-inflammatory signalling and drive neutrophil apoptosis," European Journal of Immunology, vol.
Harlow, "Distinct roles for cyclin-dependent kinases in cell cycle control," Science, vol.
Noble, "Structure-based design of cyclin-dependent kinase inhibitors," Pharmacology and Therapeutics, vol.
Takeda et al., "Neuron-specific phosphorylation of Alzheimer's [beta]-amyloid precursor protein by cyclin-dependent kinase 5, " Journal of Neurochemistry, vol.
Cyclin-dependent kinases regulate the antiproliferative function of Smads.
p27 is regarded as a cyclin-dependent kinase inhibitor of the G1-to-S cell cycle progression by suppressing the kinase activity of cyclin/cyclin-dependent kinase complex.
Some of the non-biological drugs, known as Cyclin-dependent kinase (CDK) inhibitors, are currently being tested for use in cancer treatment.
"Altered prostatic epithelial proliferation and apoptosis, prostatic development and serum testosterone in mice lacking cyclin-dependent kinase inhibitors," Biology of Reproduction 73(5): 951-958.
Melanoma and breast cancer are fairly common bedfellows in familial cancer syndromes, and both types of cancer have been linked with mutations in cyclin-dependent kinase inhibitor 2A, a tumor suppressor gene, in some studies of familial cancer cohorts.
Acting as a transcription factor the tetramer causes the production of protein p21 in complex with cyclin-dependent kinase (cdk2) which prevents the cell from entering the next stage of cell division (Kubbutat et al., 1998).
Japan-based global pharmaceutical company, Eisai, announced yesterday that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN(R)) following cyclin-dependent kinase (CDK) 4/6 inhibitor in community oncology practices will be presented during the 36th Miami Breast Cancer Conference (MBCC).
Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta.